Colorectal cancer-derived microvesicles modulate differentiation of human monocytes to macrophages
© Baj-Krzyworzeka et al. 2016
Received: 20 May 2015
Accepted: 18 January 2016
Published: 2 February 2016
Tumour-derived microvesicles (TMVs) are important players in tumour progression, modulating biological activity of immune cells e.g. lymphocytes, monocytes and macrophages. This phenomenon is particularly interesting in the progression of colon cancer, as macrophages in this type of tumour are relevant for the recovery processes. In the present study, the role of colon cancer cell-derived microvesicles in monocyte differentiation and activity profile (polarization) was investigated.
Monocyte-derived macrophages (MDM) were differentiated in vitro in the presence of TMVs obtained from colon cancer: Caco-2, SW620, LoVo or SW480 cell lines and analysed according to their morphology and biological functions, as defined by cytokine secretion, reactive oxygen intermediate (ROI) production and cytotoxic activity against respective colon cancer cells.
Monocytes differentiated with TMVs exhibited morphological and phenotypical characteristics of macrophages. An early contact (beginning with the first day of the in vitro culture) of monocytes with TMVs resulted in increased IL-10 secretion and only slightly elevated TNF release. Early, or prolonged contact resulted in low ROI production and low cytotoxicity against tumour cells. On the other hand, late contact of MDM with TMVs, stimulated MDM to significant TNF and IL-12 secretion, ROI production and enhanced cytotoxicity against tumour cells in vitro. In addition, differences in MDM response to TMVs from different cell lines were observed (according to cytokine secretion, ROI production and cytotoxicity against tumour cells in vitro). Biological activity, STATs phosphorylation and microRNA profiling of MDMs indicated differences in their polarization/activation status which may suggest mixed polarization type M1/M2 with the predominance of proinflammatory cells after late contact with TMVs.
Macrophage activity (polarization status) may be regulated by contact with not only tumour cells but also with TMVs. Their final polarization status depends on the contact time, and probably on the vesicle “cargo”, as signified by the distinct impact of TMVs which enabled the switching of MDM maturation to regulatory macrophages.
KeywordsTumour-derived microvesicles Macrophages Monocytes Regulatory cells
Colorectal cancer is the third most common cancer and the fourth most frequent cause of cancer deaths worldwide [1, 2]. This type of tumour occurs generally after the age of 50 and in most cases is sporadic, however, the occurrence of genetic or epigenetic causes along with the inflammatory microenvironment support colorectal cancer development . The infiltrating leukocytes, mainly monocytes, which give rise to macrophages, are the hallmarks of this process . The majority of macrophages infiltrating neoplastic tissue (TAM, tumour associated macrophages) have phenotype characteristics of M2 polarized cells, which are known to participate in each step of cancer progression including dissemination, seeding and metastasis formation . The level of their infiltration is used as an independent prognostic factor in many tumour types . However, it should be noted that in case of colorectal cancers, a strong macrophage infiltration does not necessarily correlate negatively with patients’ survival [4, 7, 8]. This may be associated with proinflammatory TAMs, which play an antitumour role, leading to a favourable prognosis . Different biological properties of macrophages could be associated with distinct factors (growth factors, cytokines etc.) in their microenvironment during the differentiation process . The tumour microenvironment is a very complex system of cell to cell interplay complemented by cellular interactions with the extracellular environment. Tumour cells are essential players in these processes, however, other factors should be also taken under consideration. One of the most intriguing factors are ubiquitous extracellular vesicles (EVs). During tumour progression, monocytes in blood, as well as macrophages in the tumour bed, are exposed to EVs released by nearby cells [11, 12] to body fluids [13, 14]. EVs are defined as membrane fragments of various shapes released by cells during their lifespan. Using the size and origin criteria, EVs are classified into two groups: exosomes, which are smaller (30–100 nm), more homogeneous in size and released by the endosomal compartment, and ectosomes, also known as microvesicles (MVs) , which are larger (0.1–1 μm)  and mainly originated from plasma membranes. EVs are also released by tumour cells, thus, impacting the activity of blood monocytes and TAM in tumour bed . Based on their cargo (proteins, growth factors, mRNA and microRNAs) EV are regarded as “messengers” [12–15], which may affect biological activity of macrophages. miRNAs deserve special attention as they may regulate all differentiation steps and change the activation status of macrophages . In the present study, we asked whether TMVs released by colon cancer cell lines (with different growth potential) may influence monocyte differentiation, thus, affecting their activity/polarization status. In another words, we asked, if TMVs, as tumour “go-between” present in body fluids/tumour environment, may direct/educate monocytes during their differentiation. Our results indicate an important role of TMVs in this process and suggest that TMVs origin and the time of their “first contact” with monocytes/macrophages are crucial for their ultimate activity and function.
Isolation of monocytes
Human peripheral blood mononuclear cells (PBMCs) were isolated from EDTA-blood of healthy donors by the Ficoll/Isopaque (Pharmacia, Uppsala, Sweden) density gradient centrifugation. Monocytes were separated from PBMCs by counter-flow centrifugal elutriation with the JE-6B elutriation system equipped with a 5 ml Sanderson separation chamber (Beckman-Coulter, Palo Alto, CA), as previously described . Monocytes were suspended in RPMI 1640 culture medium (PAA Laboratories, Pasching, Germany) with gentamycin (Sigma, St. Louis, MO) (25 μg/ml). Purity of monocytes was over 95 %, as judged by staining with anti-CD14 mAb (BD Biosciences Pharmingen, San Diego, CA) and flow cytometry analysis (FACSCanto BD Biosciences Immunocytometry Systems, San Jose, CA). The study was approved by the local Jagiellonian University Ethical Committee (No. KBET/160/b/2011).
Isolation of TMVs
TMVs were obtained from the following human colon cancer cell lines: Caco-2, SW480, SW620 and LoVo as previously described . The cell lines were a generous gift from prof. Caroline Dive (Paterson Institute for Cancer Research, The University of Manchester). Cell lines differed in malignancy potential as Caco-2 was described as poorly aggressive, SW480-with low metastatic ability, SW620-high metastatic ability and LoVo-undifferentiated. Cells were cultured by bi-weekly passages in RPMI 1640 (Caco-2 and LoVo) or DMEM (SW480 and SW620) (PAA) with 5 % FBS (foetal bovine serum, Biowest, Nuaille, France) centrifuged before the use at 50,000×g for bovine-derived MVs depletion. Cell lines were regularly tested for Mycoplasma sp. contamination by using PCR-ELISA kit according to the manufacturer’s protocol (Roche, Mannheim, Germany). Supernatants from well-grown cell cultures were collected, centrifuged at 2000×g for 20 min to remove cell debris and then centrifuged again at 50,000×g (RC28S, Sorvall, Newton, CT) for 1 h at 4 °C. Pellets were washed twice in PBS to remove FBS and finally resuspended in serum-free medium. Quantification of TMVs proteins was evaluated by the Bradford method (BioRad, Hercules, CA). TMVs were tested for endotoxin contamination by the Limulus test according to the manufacturer’s instruction (Charles River Laboratories, Inc., Wilmington, MA) and stored at −20 °C until use. As an additional control for some experiments MVs from non-malignant urothelial cells HCV-29 were used. To simplify, TMVs were named according to their cell line origin e.g. TMVs released from Caco-2 as TMVCaco2, from LoVo-TMVLoVo, from SW480-TMVSW480, from SW620 as TMVSW620 and from HCV-29 as MVHCV.
Differentiation of monocytes to monocyte-derived macrophages (MDM)
Morphology and phenotype of MDM
The morphology of macrophages was investigated daily by phase contrast microscopy (600× magnification) Olympus IX70 (Olympus Corp. PA). MDM morphology was assessed using cytospin slides stained for 3 min with the Wright’s dye (Merck, Darmstadt, Germany) at the last day of culture by light microscopy (Olympus BX51). Phenotype analysis was performed at day 7 using flow cytometry. The following monoclonal antibodies (mAbs) were used: APC-labelled anti-CD14, FITC-labelled anti-CD33, -CD80, -CD15, PE-labelled anti-CD1a, -CD206, -CD86, -CD11b, PerCP-labelled anti-HLA-DR, PerCP-Cy5.5-labelled anti-CD163, all from BD Pharmingen. Antibodies from R&D System: FITC-labelled anti-CD115 (MCSF-R), PE-labelled anti-CD36. For intracellular staining (CD68 FITC) MDM were fixed with Cytofix and permeabilised with PermWash buffers, both from BD Pharmingen. CD68 staining was done using mAb from Dako Cytomation (Glostrup, Denmark). Additionally, kinetics of CD206 expression was examined on a daily basis using flow cytometry. All antibodies were used in saturating concentrations with appropriate isotype-matched controls. MDM were incubated with mAbs for 30 min at 4 °C, washed and then analysed in FACSCanto flow cytometer.
Supernatants obtained on day 7 of the MDM culture were collected and the concentration of TNF, IL-10 and IL-12 was measured by the following matched mAbs pairs for ELISA (BD Pharmingen): for TNF-MAb1 (capture) and MAb11 (detection), for IL-10-JES3-9d7 (capture) and JES-12G8 (detection) and for IL-12p40/p70-C8.3 (capture) and C8.6 (detection). Recombinant human cytokines (all from BD Pharmingen) were used as standards. Tests were performed according to the manufacturer’s protocol and results were obtained using the ELISA reader (BioTek Instruments, Vinooski, VT) at 492 vs 630 nm wavelength. Detection level for TNF was 20 pg/ml, and 10 pg/ml for IL-10, IL-12p40/p70.
microRNA (miR) expression
MDM differentiated in the presence of TMVs (TMVSW480, TMVSW620, TMVLoVo and TMVCaco2) were tested for miR expression profile. The total RNA was extracted from MDM, MDM + TMVs (after 7 days of culture) and TMVs alone with mirVana™ miRNA Isolation Kit (Ambion, Life Technologies, Austin, TX) according to the manufacturer’s protocol. The first strand cDNA was obtained from the total RNA (400 ng) samples with Megaplex™ RT Primers (pool A and B, Applied Biosystems, Foster City, CA). TaqMan Array Micro RNA Card Set v3.0 were used to detect expression of human miRs in preliminary studies. Real-time PCR was performed using the 7900HT System (Applied Biosystems). For miRs, which major differences in expression were detected in preliminary experiments (miR-9,-21,-155,-378,-511) individual real-time PCRs (TaqMan Gene Expression Assays, Applied Biosystems) were performed. All experiments were performed three times and the PCR reactions were performed in triplicates using the 7300 Real-Time PCR System (Applied Biosystems). Reverse transcription was performed as described above (Megaplex RT primers pool A were used for miR-9,-21,-155,-511 and U6 as a control, Megaplex RT primers pool B were used for miR-378 and U6). The fluorescent signals generated during the informative log-linear phase were used to calculate the relative amount of miR. U6 was used as a control for each PCR run and the miR expression was calculated as a fold difference from that of control MDM normalized by U6 results (2−ΔΔCT).
Determination of ROI production by flow cytometry
The intracellular production of ROI was measured by flow cytometry using oxidation-sensitive fluorescent probe hydroethidine (HE, Sigma). After 7 days, MDM expanded alone or in the presence of TMVs (added in the described regimen) were preincubated with 10 µM HE for 30 min and stimulated with phorbol 12-myristate 13-acetate (4 µM PMA, Sigma) for 10 min, after which cells were washed and analysed immediately with FACSCanto flow cytometer.
To assess the master regulators in signalling processes that lead towards M1 (STAT1, STAT5) or M2 (STAT3, STAT6) differentiation Western blotting technique was employed. Monocytes were stimulated with TMVs for 30′, 2 h, 4 h and 7 h at day 0 or day 6. After stimulation cells were lysed in M-PER lysing buffer (Pierce, Rockford, IL) containing protease inhibitor cocktail (Roche). As a control unstimulated monocytes/MDM were used. The concentration of samples was measured using the Bradford kit (Bio-Rad) as per manufacturer’s instruction. 20 µg of isolated protein was mixed with NuPAGE LDS Sample Buffer (4×) (Life Technologies, Carlsbad, CA) and NuPAGE Sample Reducing Agent (10×) (Life Technologies). Samples were heated (70 °C, 10 min) and electrophoresed in 12 % polyacrylamide gel containing SDS. Next, electrophoresed samples were transferred onto the polyvinylidene fluoride membrane (Bio-Rad). Then, after blocking for 1 h at room temperature in Tris buffered saline (TBS) with 0.1 % Tween-20 (Sigma, St. Louis, MO) and 1 % bovine serum albumin (BSA, Sigma) the membranes were incubated overnight at 4 °C with rabbit polyclonal antibodies: anti-phopspho-STAT1 (Tyr701), anti-phospho-STAT3 (Tyr705), anti-phospho-STAT5 (Tyr694), anti-total STAT1, anti-total STAT3 and anti-total STAT5 (all antibodies were purchased from Cell Signaling, Danvers, MA) diluted 1:1000. After incubation, membranes were washed in TBS supplemented with BSA and Tween-20 and incubated for 1 h at room temperature with secondary goat anti-rabbit antibody (dilution 1:2500) conjugated with horseradish peroxidase (Cell Signaling). The protein bands were visualized with the SuperSignal West Pico Chemiluminescence Substrate kit (Pierce) according to the manufacturer’s protocol and analysed with KODAK GEL LOGIC 1500 Digital Imaging System (KODAK, Rochester, NY).
MDM cytotoxicity against tumour cells was tested, as described previously . Briefly, after 7 day culture, MDM (5×104/well) grown alone or with TMVs were cocultured with the appropriate tumour cells (autologous) (2×104/well) for 48 h, after which the culture medium was removed and 100 μl of 1, 3-[4,5-dimetylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT, 2 mg/ml, Sigma) dye solution was added for 4 h. The experiment was repeated 5 times in triplicates. Formed formazan was extracted with isopropyl alcohol (Fluka Chemie AG, Buchs, Switzerland) containing 0,04 N HCl and its content was measured spectrophotometrically (absorbance at 570 and 630 nm). The percentage of cytotoxicity was calculated according to the formula described previously .
Statistical analysis was performed by nonparametric Mann–Whitney test. Differences were considered significant at p < 0.05.
Monocytes in the presence of TMVs differentiate to macrophages
Phenotype analysis of MDM differentiated in the presence of TMVs. Percentages of positive cells (mean ± SD) in 5 independent cultures are presented
MDM + TMV0d
MDM + TMV036d
MDM + TMV6d
30 ± 18
46 ± 24
42 ± 20
38 ± 23
45 ± 23
45 ± 23
38 ± 14
29 ± 13
47 ± 20
15 ± 8
32 ± 16
15 ± 9
24 ± 17
3 ± 7
16 ± 17*
14 ± 14*
6 ± 7
41 ± 16*
14 ± 8*
24 ± 10*
10 ± 8
49 ± 18*
20 ± 19*
14 ± 9*
3 ± 3
26 ± 15*
56 ± 16
46 ± 9
51 ± 22
53 ± 19
27 ± 2*
43 ± 13*
54 ± 35
56 ± 19
18 ± 5*
81 ± 6*
72 ± 11*
67 ± 16
44 ± 17
79 ± 8
55 ± 7*
54 ± 11*
70 ± 10
63 ± 25
42 ± 9
46 ± 5*
66 ± 15
64 ± 17
71 ± 31
84 ± 8
81 ± 9
64 ± 25
15 ± 9
6 ± 1*
12 ± 4
6 ± 1*
3 ± 3*
6 ± 1*
11 ± 7
8 ± 3
4 ± 4*
24 ± 22
35 ± 12*
16 ± 16
6 ± 1*
48 ± 13
79 ± 16*
79 ± 12*
76 ± 21*
69 ± 6*
86 ± 6*
78 ± 11*
74 ± 25
73 ± 7*
62 ± 20
65 ± 17
65 ± 22
52 ± 7
10 ± 8
10 ± 7
11 ± 11
10 ± 7
17 ± 4
9 ± 4
9 ± 5
9 ± 4
9 ± 5
10 ± 9
6 ± 5
10 ± 9
3 ± 4
MDM + TMV0d and MDM + TMV6d differ in microRNA expression
TMVs carry microRNA involved in macrophage differentiation
In parallel to miRs analysis in MDM, miRs expression in TMVs was determined, however, only miRs detected at CT below 31 were analysed (set arbitrarily, average CT presented in brackets). The TMVCaco2 carried miR: −106a (27, 92), −146b (30, 31), −155 (27, 82), −223 (30, 15), and −378 (25, 31), TMVSW480-miR-106a (24, 88), −106b (29, 29), −146a (25, 83), −21 (28, 16), −222 (26, 12), −223 (27, 62), −26a (28, 02), −378 (29, 23) and −9 (30, 77), TMVSW620 −106a (24, 59), −146a (30, 06), −21 (30, 28), −222 (25, 93), −223 (29, 13), TMVLoVo-miR-106a (30, 76), −222 (29, 74), −328 (28, 70). miR-511 was not detected. Data are presented as a heat map (Fig. 5f).
TMVs induce secretion of cytokines by MDM
MDM + TMV6d produce high amounts of ROI
TMVs induce phosporylation of STAT1 and STAT3
TMVs change cytotoxic/cytostatic activity of MDM
It was previously reported that TMVs interact with human monocytes, leading to their activation . The present study addressed the question whether TMVs may have an impact on monocyte differentiation and if so, what type of myeloid cells is generated as the result of this process. In the mouse model, tumour derived exosomes directed monocytes differentiation into myeloid-derived suppressor cells (MDSC), which were characterized by the expression of CD11b(+)Gr-1(+) markers . Moreover, Valenti et al. showed impaired differentiation of monocytes to dendritic cells in the presence of tumour exosomes and cytokines (GM-CSF, IL-4) . This study shows that TMVs alone may impact differentiation of monocytes to macrophages, however, it should be kept in mind that we used a mixed population of vesicles, not just limited to exosomes. Depending on the time of the “first” contact between monocytes/MDM and TMVs (but not “normal” MV), differences in MDM morphology, phenotype, cytokine secretion, ROI production and cytotoxicity against tumour cells in vitro were observed. We observed that TMVs present in the MDM culture induced transient cell cluster formation. The mechanism of this phenomenon is not clear, however, we suggest that this is related to hyaluronan, which is present in TMVs and MVs . MDM differentiated in the presence of TMVs are bigger and more granular than control MDM. All of them showed intracellular expression of CD68 and surface expression of CD14, however, the highest CD14 expression (marker of M1 cells ) was observed on MDM + TMV6d.
Expression of CD206 was significantly higher on MDM + TMV0d and MDM + TMV036d than on control MDM and MDM + TMV6d. Lower expression of HLA-DR on MDM + TMV 6d was observed, but it was not significant. CD80 expression was elevated by all TMVs except for TMVSW620 (highly metastatic cell line). Expression of CD86 was significantly higher on MDM + TMV 6d. TMVSW480 decreased expression of CD163 on MDM. No differences in CD115 (M-CSF R) expression were observed after contact with TMVs. We should stress out that these observation are specific for TMVs and not observed after contact with control MVs used in our study.
The phenotype of MDM + TMV6d (low HLA-DR, CD206, high CD86) combined with morphological features may indicate TAM with mixed polarization. Simultaneous phosphorylation of STAT1 and STAT3, combined with the expression of miR-155 and miR-9 supports this hypothesis. The distinct expression of HLA-DR on TAM was also observed by others  and usually it was attributed to hypoxia conditions in the tumour bed . Based on our findings, we suggest, that the HLA-DR expression may be also influenced by the previous stimulation/contact with TMVs. In parallel, elevated expression of CD86, correlates with clinical data that most macrophages distributed along the invasive margin of colorectal carcinoma are CD86+ [29, 30]. Heterogeneity of TAM phenotype was described in different tumour types  and at different locations of the same tumour [32, 33] e.g. in colon cancer patients, CD80+, CD86+ and HLA-DR+ , as well as CD163+, CD86+, CCR2+ cells were described .
The elevated expression of CD206 (M2 marker) on MDM + TMV0d and MDM + TMV036d may indicate M2 polarization. Control MDM were grown in culture medium without growth factors to develop M0 phenotype , however, the elevated expression of CD206 may indicate spontaneous predominance of M2 over M1 phenotype in these cells . The upregulation of the mannose receptor in tumour macrophages was accompanied by increase of miR-511-3p , which corroborates our data (Fig. 5e). Moreover, we observed dynamic increase of CD206 expression at day 1 of culture, which correlated with dynamic changes in different miR expression during the first day of differentiation .
Low expression of CD115 (M-CSFR) is rather a sign of non-M2 cells, as M-CSF directed differentiation towards M2 . The decrease of CD115 on macrophages was previously observed by Rovida et al. and explained by its shedding by proteases from macrophages undergoing activation .
Different phenotype of macrophages infiltrating tumour site may allow to predict their activation status, which subsequently may anticipate their response to tumour. In fact, TAM phenotyping may be more informative than density/number of infiltrating cells for patient prognosis [33, 37].
In this study the activation of MDM was measured by cytokine secretion, ROI production and cytotoxicity against tumour cells. Cytokine secretion by MDM and their phenotype, depended on time and frequency of the contact with TMVs and TMVs origin. The strongest secretion of TNF and IL-12 was observed when TMVs were added at the final stage of differentiation (MDM + TMV6d). In comparison, MDM + TMV0d released significantly more IL-10 than other types of MDM. MDM differentiated in the presence of TMVSW480 were the weakest producers of IL-10, while MDM + TMVLoVo6d and MDM + TMVSW4806d, produced the highest amounts of TNF, which may be related to their growth potential. It is of note that MDM differentiated after a prolonged contact with TMVs (MDM + TMV036d) secreted the lowest amounts of TNF and IL-12. This is in keeping with previously described deactivation of monocytes/macrophages by tumour cells , which may be observed also after TMVs contact, presumably via their hyaluronan component .
The most potent ROI producers were MDM + TMV6d, but it seemed to be TMVs-origin dependent as TMVCaco2 did not induce production of ROI. MDM + TMV6d were more cytotoxic/cytostatic to tumour cells, most likely due to the cytotoxicity mediated by ROI and proinflammatory cytokines. Our data corroborates with the observation that TAM isolated from spheroids of human colorectal cancer expressed antitumour potential probably via secretion of proinflammatory mediators .
The observed differences between MDM + TMV0d and MDM + TMV6d (early and late contact) may be due to the regulation of the differentiation process via e.g. microRNA. The first scenario is, that the fate of microRNA in MDM is influenced not only by cytokines and nearby cells [18, 40] but also by TMVs present in the local environment. In keeping with this, we observed different miR expression profile in MDM + TMV0d and MDM + TMV6d. MDM after early contact with TMVs had upregulated miRs expression characteristic for M2-like cells (miR-21,-511,-9). The highest expression of these miRs was observed in the case of TMVCaco2, which induced differentiation of MDM with a lower proinflammatory capacity. MDM + TMV6d expressed higher levels of miR-155 in comparison to MDM + TMV0d and MDM control for all tested TMVs. MDM + TMVLoVo6d and MDM + TMVSW4806d expressed also more miR-378. Taken together, the miR profile may suggest predominance of M2 cells after early contact and more proinflamatory cells after late contact with TMVs. Morphology of MDM + TMV6d (“fried egg”-shaped cells), and the cytokine secretion support the hypothesis of switch (at least in part of the cells) towards proinflammatory activity.
The second possibility, which complements the first one, is that miRNAs are carried by TMVs themselves. MVs were described before as safe transporters for miRNAs involved in regulation of cellular differentiation [41, 42]. TMVs used in our experiments carried miR-106a, -146a, -155, -222, -223, -378 which are crucial for macrophage differentiation and activation processes [43, 44], however, quantitative assessment of this phenomenon requires further confirmation. The direct transfer of miR cannot be excluded, except for miR-511 which was not detected in TMVs.
Our and others’  results support the observation that TAM may have distinct properties, which do not fit perfectly the classical M1/M2 definition. We conclude that MDM differentiated in the presence of TMVs represent a mixed phenotype (M1/M2). We suggest that late contact with TMVs predisposes MDM to more proinflammatory activity. Hypothetical scenario is presented in Fig. 10. Furthermore, we suggest that biological activity of MDM is more important than their number and phenotype during tumour progression. Although, we do not have a formal proof, we suspect that removal of TMVs from blood in order to delay the first contact with monocytes, may improve macrophage activity against cancer. The idea is not new as Ichim et al. proposed a physical approach in order to remove tumour exosomes from the body fluids of the cancer patients . Also, the isolation of monocytes followed by their differentiation ex vivo and “education” with TMVs may increase their anti-tumour potential. Again, the idea was already implemented, but with dendritic cells .
Taken together, MDM differentiated in vitro with TMVs fit the “colour wheel” classification of macrophage polarization as different “shades” of green , which we think, may be induced by TMVs.
TMVs modulated activity of monocytes and their differentiation towards macrophages. The final polarization status of macrophages was dependent on TMVs origin and the time of contact with them. We suggest, that in the case of colon cancer, late contact of MDM with TMVs induced their mix polarization with significant proinflammatory potential.
foetal bovine serum
mean fluorescence intensity
tumour necrosis factor
transforming growth factor beta
phorbol 12-myristate 13-acetate
reactive oxygen intermediates
myeloid-derived suppressor cells
tumour associated macrophages
granulocyte-macrophage colony-stimulating factor
macrophage colony-stimulating factor
MBK designed the study, participated in data acquisition, performed analysis and prepared the first version of manuscript, BM was responsible for the cell culture and TMVs isolation, RSz and JB participated in data analysis and manuscript preparation, MS (Marcin Surmiak) participated in data acquisition, KW performed the Western blot, MS (Maciej Siedlar) improved the manuscript with valuable comments. All authors read and approved the final manuscript.
This study was supported by the National Science Center of Poland [N N401 616040]. Publication of this study was supported by the Leading National Research Center (KNOW), Faculty of Medicine, Jagiellonian University Medical College. This article is based upon work from the COST Action BM1404 Mye-EUNITER (http://www.mye-euniter.eu, http://www.mye-euniter.eu), supported by COST (European Cooperation in Science and Technology). We wish to thank Prof. Marek Sanak and prof. Marcin Majka for the opportunity of real time microRNA analysis and Ms. Irena Ruggiero, Barbara Hajto and Mariola Ożóg for the excellent technical support.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet. 2005;14:153–65.View ArticleGoogle Scholar
- Swiderska M, Choromańska B, Dąbrowska E, Konarzewska-Duchnowska E, Choromańska K, Szczurko G, Myśliwiec P, Dadan J, Ladny JR, Zwierz K. The diagnostics of colorectal cancer. Contemp Oncol (Pozn). 2014;18:1–6.Google Scholar
- Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383:1490–502.View ArticlePubMedGoogle Scholar
- Mantovani A, Germano G, Marchesi F, Locatelli M, Biswas SK. Cancer-promoting tumour-associated macrophages: new vistas and open questions. Eur J Immunol. 2011;41:2522–5.View ArticlePubMedGoogle Scholar
- Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumour-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–55.View ArticlePubMedGoogle Scholar
- Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71–8.View ArticlePubMedGoogle Scholar
- Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumour front correlates with improved survival in colon cancer. Clin Cancer Res. 2007;13:1472–9.View ArticlePubMedGoogle Scholar
- Zhou Q, Peng RQ, Wu XJ, Xia Q, Hou JH, Ding Y, Zhou QM, Zhang X, Pang ZZ, Wan DS, Zeng YX, Zhang XS. The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J Transl Med. 2010;8:13.PubMed CentralView ArticlePubMedGoogle Scholar
- Ong SM, Tan SM, Beretta O, Jiang D, Yeap WH, Tai JJ, et al. Macrophages in human colorectal cancer are pro-inflammatory and prime T cells towards an anti-tumour type-1 inflammatory response. Eur J Immunol. 2012;42:89–100.View ArticlePubMedGoogle Scholar
- Mantovani A, Locati M. Tumour-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. Arterioscler Thromb Vasc Biol. 2013;33:1478–83.View ArticlePubMedGoogle Scholar
- Antonyak MA, Cerione RA. Microvesicles as mediators of intercellular communication in cancer. Methods Mol Biol. 2014;1165:147–73.View ArticlePubMedGoogle Scholar
- Inal JM, Ansa-Addo EA, Stratton D, Kholia S, Antwi-Baffour SS, Jorfi S, Lange S. Microvesicles in health and disease. Arch Immunol Ther Exp (Warsz). 2012;60:107–21.View ArticleGoogle Scholar
- Lee TH, D’Asti E, Magnus N, Al-Nedawi K, Meehan B, Rak J. Microvesicles as mediators of intercellular communication in cancer–the emerging science of cellular ‘debris’. Semin Immunopathol. 2011;33:455–67.View ArticlePubMedGoogle Scholar
- Ratajczak J, Wysoczyński M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communications. Leukemia. 2006;20:1487–95.View ArticlePubMedGoogle Scholar
- Rak J. Microparticles in cancer. Semin Thromb Hemostasis. 2010;36:888–906.View ArticleGoogle Scholar
- Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2:569–79.PubMedGoogle Scholar
- Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Zembala M. Tumour - derived microvesicles modulate biological activity of human monocytes. Immunol Lett. 2007;113:76–82.View ArticlePubMedGoogle Scholar
- Eigsti RL, Sudan B, Wilson ME, Graff JW. Regulation of activation-associated microRNA accumulation rates during monocyte-to-macrophage differentiation. J Biol Chem. 2014;289:28433–47.PubMed CentralView ArticlePubMedGoogle Scholar
- Mytar B, Siedlar M, Woloszyn M, Colizzi V, Zembala M. Cross-talk between human monocytes and cancer cells during reactive oxygen intermediates generation: the essential role of hyaluronan. Int J Cancer. 2001;94:727–32.View ArticlePubMedGoogle Scholar
- Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Urbanowicz B, Brański P, Ratajczak MZ, Zembala M. Tumour-derived microvesicles carry serveral surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother. 2006;55:808–18.View ArticlePubMedGoogle Scholar
- Mia S, Warnecke A, Zhang XM, Malmström V, Harris RA. Optimized protocol for human M2 macrophages using M-CSF and IL-4/IL-10/TGFβ yields a dominant immunosuppressive phenotype. Scand J Immunol. 2014;79:305–14.PubMed CentralView ArticlePubMedGoogle Scholar
- Mytar B, Wołoszyn M, Szatanek R, Baj-Krzyworzeka M, Siedlar M, Ruggiero I, Więckiewicz J, Zembala M. Tumour cell-induced deactivation of human monocytes. J Leukoc Biol. 2003;74:1094–101.View ArticlePubMedGoogle Scholar
- Xiang X, Poliakov A, Liu C, Liu Y, Deng ZB, Wang J, Cheng Z, Shah SV, Wang GJ, Zhang L, Grizzle WE, Mobley J, Zhang HG. Induction of myeloid-derived suppressor cells by tumour exosomes. Int J Cancer. 2009;124:2621–33.PubMed CentralView ArticlePubMedGoogle Scholar
- Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, Villa A, Corbelli A, Fais S, Parmiani G. Rivoltini L Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res. 2006;66:9290–8.View ArticlePubMedGoogle Scholar
- Lenart M, Rutkowska-Zapała M, Baj-Krzyworzeka M, Szatanek R, Węglarczyk K, Smallie T, Ziegler-Heitbrock L, Zembala M, Siedlar M. Hyaluronan carried by tumor-derived microvesicles induces IL-10 production in classical (CD14 ++CD16-) monocytes via PI3 K/Akt/mTOR-dependent signalling pathway. Immunobiology. 2015. doi:10.1016/j.imbio.2015.06.019 (pii: S0171–2985(15)30018-8).PubMedGoogle Scholar
- Beyer M, Mallmann MR, Xue J, Staratschek-Jox A, Vorholt D, Krebs W, Sommer D, Sander J, Mertens C, Nino-Castro A, Schmidt SV, Schultze JL. High-resolution transcriptome of human macrophages. PLoS One. 2012;7:e.45466.View ArticleGoogle Scholar
- Wang B, Li Q, Qin L, Zhao S, Wang J, Chen X. Transition of tumour-associated macrophages from MHC class II(hi) to MHC class II(low) mediates tumour progression in mice. BMC Immunol. 2011;4(12):43.View ArticleGoogle Scholar
- Biswas SK, Allavena P, Mantovani A. Tumour-associated macrophages:functional diversity, clinical significance and open questions. Semin Immunopathol. 2013;35:585–600.View ArticlePubMedGoogle Scholar
- Ohtani H. Focus on TILs: prognostic significance of tumour infiltrating lymphocytes in human colorectal cancer. Cancer Immun. 2007;21(7):4.Google Scholar
- Ohtani H, Naito Y, Saito K, Nagura H. Expression of costimulatory molecules B7-1 and B7-2 by macrophages along invasive margin of colon cancer: a possible antitumour immunity? Lab Invest. 1997;77:231–41.PubMedGoogle Scholar
- Squadrito ML, De Palma M. Macrophage regulation of tumour angiogenesis: implications for cancer therapy. Mol Aspects Med. 2011;32:123–45.View ArticlePubMedGoogle Scholar
- Lewis CE. PollardJW. Distinct role of macrophages in different tumour microenvironments. Cancer Res. 2006;66:605–12.View ArticlePubMedGoogle Scholar
- Van Overmeire E, Laoui D, Keirsse J, Van Ginderachter JA, Sarukhan A. Mechanisms driving macrophage diversity and specialization in distinct tumour microenvironments and parallelisms with other tissues. Front Immunol. 2014;26(5):127.Google Scholar
- Kinouchi M, Miura K, Mizoi T, Ishida K, Fujibuchi W, Sasaki H, Ohnuma S, Saito K, Katayose Y, Naitoh T, Motoi F, Shiiba K, Egawa S, Shibata C, Unno M. Infiltration of CD40-positive tumour-associated macrophages indicates a favorable prognosis in colorectal cancer patients. Hepatogastroenterology. 2013;60:83–8.PubMedGoogle Scholar
- Tedesco S, Bolego C, Toniolo A, Nassi A, Fadini GP, Locati M, Cignarella A. Phenotypic activation and pharmacological outcomes of spontaneously differentiated human monocyte-derived macrophages. Immunobiology. 2014;220:545–54 (pii: S0171-2985(14)00277-0).View ArticlePubMedGoogle Scholar
- Squadrito ML, Pucci F, Magri L, Moi D, Gilfillan GD, Ranghetti A, Casazza A, Mazzone M, Lyle R, Naldini L, De Palma M. miR-511-3p modulates genetic programs of tumour-associated macrophages. J Immunol. 2012;161:6250–7.Google Scholar
- Lin EY, Pollard JW. Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer. 2004;90:2053–7.PubMed CentralView ArticlePubMedGoogle Scholar
- Rovida E, Paccagnini A, Del Rosso M, Peschon J. Dello Sbarba P. TNF-alpha converting enzyme cleaves the macrophage colony-stimulating factor receptor in macrophages undergoing activation. J Immunol. 2001;166:1583–9.View ArticlePubMedGoogle Scholar
- Kuang DM, Wu Y, Chen N, Cheng J, Zhuang SM, Zheng L. Tumour-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood. 2007;110:587–95.View ArticlePubMedGoogle Scholar
- Graff JW, Dickson AM, Clay G, McCaffrey AP, Wilson ME. Identifying functional microRNAs in macrophages with polarized phenotypes. J Biol Chem. 2012;287:21816–25.PubMed CentralView ArticlePubMedGoogle Scholar
- Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer. 2010;26:306.View ArticleGoogle Scholar
- Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One. 2008;3:e3694.PubMed CentralView ArticlePubMedGoogle Scholar
- Squadrito ML, Etzrodt M, De Palma M, Pittet MJ. MicroRNA-mediated control of macrophages and its implications for cancer. Trends Immunol. 2013;34:350–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Ismail N, Wang Y, Dakhlalah D, Moldovan L, Agarwal K, Batte K, Shah P, Wisler J, Euband TD, Tridandapani S, Paulaitis E, Piper MG, Marsh CB. Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. Blood. 2013;121:984–95.PubMed CentralView ArticlePubMedGoogle Scholar
- Dumont P, Berton A, Nagy N. SandrasF, Tinton S, Demetter P, Mascart F, Allaoui A, Decaestecker C, Salmon I. Expression of galectin-3 in the tumour immune response in colon cancer. Lab Invest. 2008;88:896–906.View ArticlePubMedGoogle Scholar
- Ichim TE, Zhong Z, Kaushal S, Zheng X, Ren X, Hao X, Joyce JA, Hanley HH, Riordan NH, Koropatnick J, Bogin V, Minev BR, Min WP, Tullis RH. Exosomes as a tumour immune escape mechanism: possible therapeutic implications. J Transl Med. 2008;6:37.PubMed CentralView ArticlePubMedGoogle Scholar
- Dai S, Wei B, Wu Z, Zhou X, Wei X, Huang H, Li G. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther. 2008;16:782–90.View ArticlePubMedGoogle Scholar
- Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–69.PubMed CentralView ArticlePubMedGoogle Scholar